[
  {
    "ts": null,
    "headline": "4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off",
    "summary": "It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time.  With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio.  With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).",
    "url": "https://finnhub.io/api/news?id=4b343700d61184c8820b2648510b9b4b9daead66835bdbcda884421d1aead106",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745705100,
      "headline": "4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off",
      "id": 134104516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time.  With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio.  With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).",
      "url": "https://finnhub.io/api/news?id=4b343700d61184c8820b2648510b9b4b9daead66835bdbcda884421d1aead106"
    }
  },
  {
    "ts": null,
    "headline": "China weighs U.S. tariff exemptions, Alphabet reports Q1 beat: Morning Buzz",
    "summary": "The major averages were mixed near noon following several days of gains as investors process the latest batch of earnings reports, including a notable one from a big tech bellwether. Optimism over easing U.S.-China trade tensions, particularly with China reportedly considering tariff exemptions for certain American products, is also being weighed, though President Trump said he would consider it a “total victory” if the U.S. has high tariffs of 20%-50% on foreign nations a year from now, accordi",
    "url": "https://finnhub.io/api/news?id=45dda7f219845d362c372d9ea360e40eaed019f671bd925f18f86699e541d72a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745684455,
      "headline": "China weighs U.S. tariff exemptions, Alphabet reports Q1 beat: Morning Buzz",
      "id": 134103528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The major averages were mixed near noon following several days of gains as investors process the latest batch of earnings reports, including a notable one from a big tech bellwether. Optimism over easing U.S.-China trade tensions, particularly with China reportedly considering tariff exemptions for certain American products, is also being weighed, though President Trump said he would consider it a “total victory” if the U.S. has high tariffs of 20%-50% on foreign nations a year from now, accordi",
      "url": "https://finnhub.io/api/news?id=45dda7f219845d362c372d9ea360e40eaed019f671bd925f18f86699e541d72a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc (ABBV) Q1 2025 Earnings Call Highlights: Strong Growth in Immunology and ...",
    "summary": "AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in Humira and aesthetics.",
    "url": "https://finnhub.io/api/news?id=d42e07f4fd3d97b078b18c64a85d2c9809076b046852aede6b369d21f7ad6605",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745651057,
      "headline": "AbbVie Inc (ABBV) Q1 2025 Earnings Call Highlights: Strong Growth in Immunology and ...",
      "id": 134104518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in Humira and aesthetics.",
      "url": "https://finnhub.io/api/news?id=d42e07f4fd3d97b078b18c64a85d2c9809076b046852aede6b369d21f7ad6605"
    }
  },
  {
    "ts": null,
    "headline": "Q1 2025 AbbVie Inc Earnings Call",
    "summary": "Q1 2025 AbbVie Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=563d121d8c07fdce20f7deee410ea9fb2d78c1e0d670e5dd57357c04c896a3bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745644277,
      "headline": "Q1 2025 AbbVie Inc Earnings Call",
      "id": 134104519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Q1 2025 AbbVie Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=563d121d8c07fdce20f7deee410ea9fb2d78c1e0d670e5dd57357c04c896a3bf"
    }
  },
  {
    "ts": null,
    "headline": "How Much Would It Take To Earn $100 A Month From AbbVie Stock",
    "summary": "AbbVie (NYSE:ABBV), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier. Don't Miss: Deloitte's f",
    "url": "https://finnhub.io/api/news?id=6ed72536064ed67923327e335fb539964edc25ccc5303d8695000bf6975cfcd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745633271,
      "headline": "How Much Would It Take To Earn $100 A Month From AbbVie Stock",
      "id": 134104520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier. Don't Miss: Deloitte's f",
      "url": "https://finnhub.io/api/news?id=6ed72536064ed67923327e335fb539964edc25ccc5303d8695000bf6975cfcd1"
    }
  }
]